Active removal of anterior segment-migrated dexamethasone implant (Ozurdex^®).

ABSTRACT: Background: Ozurdex^® (Allergan plc., Dublin, Ireland) is an intravitreal sustained-release dexamethasone (DEX) implant. The implant has been reported to migrate into the anterior chamber, potentially causing corneal decompensation. Prompt removal or relocation in the vitreous cavity is advised but troublesome due to its fragility. Several techniques exist, but elaborate setup and specialized surgical skills that are required may cause delay in treatment. We report a novel technique that avoids these shortcomings. Case presentation: A 59-year-old woman presented to the emergency department with visual loss due to an anterior chamber-migrated DEX implant and corneal edema. Using an ophthalmic viscosurgical device (OVD) and a bent 19-gauge needle, the implant has prom

SUBMITTER: Depla JAM 

PROVIDER: S-EPMC9006423 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature